FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices – Includes Caremark, Express Scripts, ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...

Recent developments in health include EU approval of Novo's Wegovy for obesity-related heart conditions, the US FDA's nod for ...

In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated ...

According to the FTC, the three largest PBMs — CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx — used their power to exclude cheaper insulin products from the menu of ...

Insulin resistance is associated with 31 different diseases and, in women, is also linked to higher odds of an early death, a study of data on hundreds of thousands of people in the UK being ...

Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and QWINT-3 Phase 3 clinical trials for once-weekly insulin efsitora alfa reached the primary endpoints against daily basal insulins ...

In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a ...

(RTTNews) - Eli Lilly and Company (LLY) Thursday announced positive topline results from the QWINT-1 and QWINT-3 phase 3 studies evaluating once weekly basal insulin efsitora alfa in adults with ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...